Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

NCT01319240 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of the combination medication insulin degludec/liraglutide in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 24 people

Who can join Ages 18–55 · male only

Timeline Started 2011-03 · est. completion 2011-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01319240 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations.

Treatments tested

insulin degludec Drug

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
insulin degludec/liraglutide Drug

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
liraglutide Drug

Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

Main thing measured	The area under insulin degludec concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01319240 ↗